In this respect, molecules that target DJ-1/Nrf2 signaling may ameliorate MS development, since dimethyl fumarate that has been FDA-approved for the treatment of MS can upregulate Nrf2 in astrocytes. Here, PARK7 is linked to myeloid sarcoma.